Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced that it has enrolled 50% of the total projected enrollment required for its Phase IIa trial to evaluate the safety and preliminary efficacy of Serdaxin™ as a central nervous system based treatment for Major Depressive Disorder (MDD). The complete trial calls for the enrollment of up to 80 patients at multiple clinical trial sites in the United States.
Popularity: unranked [?]
Related posts:
- Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial Of Serdaxin(TM) To Treat Depression
- Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial Of SerdaxinTM To Treat Depression
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
- Rexahn Pharmaceuticals Receives FDA Approval To Initiate Phase II Trial For Serdaxin In Patients With Major Depressive Disorders
- Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder
Comments
No Responses to “Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression”